<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Guide to pregabalin (Lyrica) for chronic pain - uses, dosing, and comparison to gabapentin for nerve pain.">
    <meta name="keywords" content="pregabalin, Lyrica, nerve pain medication, fibromyalgia treatment, neuropathy medication">
    <title>Pregabalin (Lyrica) | ChronicSoreness</title>
    <link rel="stylesheet" href="../css/styles.css">
</head>
<body>
    <header class="header"><nav class="nav-container"><div class="logo"><a href="../index.html"><span class="logo-icon">ðŸ’œ</span><span class="logo-text"><strong>Chronic</strong>Soreness</span></a></div><button class="mobile-menu-toggle" aria-label="Toggle menu"><span class="hamburger"></span></button><ul class="nav-menu"><li><a href="../conditions.html">Conditions</a></li><li><a href="../treatments.html">Treatments</a></li><li><a href="../medications.html">Medications</a></li><li><a href="../exercise.html">Exercise</a></li><li><a href="../nutrition.html">Nutrition</a></li><li><a href="../mental-health.html">Mental Health</a></li></ul></nav></header>
    <main id="main-content">
        <article class="page-header"><h1>Pregabalin (Lyrica)</h1><p>FDA-approved for multiple pain conditions</p></article>
        <section class="content-section">
            <div class="container">
                <h2>What Is Pregabalin?</h2>
                <p>Pregabalin is similar to gabapentin but with more predictable absorption and faster onset. It's FDA-approved for several chronic pain conditions and is considered a first-line treatment for many types of neuropathic pain.<sup>1</sup></p>

                <h2>FDA-Approved Uses</h2>
                <ul>
                    <li>Fibromyalgia</li>
                    <li>Diabetic peripheral neuropathy</li>
                    <li>Postherpetic neuralgia</li>
                    <li>Neuropathic pain from spinal cord injury</li>
                    <li>Epilepsy (adjunct)</li>
                </ul>

                <h2>Pregabalin vs. Gabapentin<sup>2</sup></h2>
                <ul>
                    <li>More linear absorption (predictable dosing)</li>
                    <li>Twice daily dosing (vs. 3 times)</li>
                    <li>Faster onset of effect</li>
                    <li>Similar efficacy</li>
                    <li>More expensive (generic now available)</li>
                    <li>Schedule V controlled substance</li>
                </ul>

                <h2>Dosing</h2>
                <ul>
                    <li><strong>Start</strong>: 75 mg twice daily or 50 mg three times daily</li>
                    <li><strong>Increase</strong>: After 3-7 days based on response</li>
                    <li><strong>Target</strong>: 150-300 mg/day</li>
                    <li><strong>Maximum</strong>: 600 mg/day</li>
                    <li>Reduce dose if kidney problems</li>
                </ul>

                <h2>Side Effects<sup>3</sup></h2>
                <ul>
                    <li>Dizziness</li>
                    <li>Drowsiness</li>
                    <li>Peripheral edema</li>
                    <li>Weight gain</li>
                    <li>Dry mouth</li>
                    <li>Blurred vision</li>
                    <li>Cognitive effects</li>
                </ul>

                <h2>Important Information</h2>
                <ul>
                    <li>Controlled substance (DEA Schedule V)</li>
                    <li>Some abuse potential</li>
                    <li>Taper gradually when stopping</li>
                    <li>May cause angioedema (rare)</li>
                </ul>

                <h2>References</h2>
                <ol>
                    <li>Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. <em>Cochrane Database Syst Rev</em>. 2019;1(1):CD007076.</li>
                    <li>Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. <em>Clin Pharmacokinet</em>. 2010;49(10):661-669.</li>
                    <li>Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. <em>J Pain</em>. 2008;9(9):792-805.</li>
                </ol>
            </div>
        </section>
    </main>
    <footer class="footer"><div class="container"><p class="disclaimer">The information provided is for educational purposes only and is not medical advice.</p><p class="copyright">Â© 2024 ChronicSoreness. All rights reserved.</p></div></footer>
    <script src="../js/main.js"></script>
</body>
</html>
